{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".60","upperLimit":".81","value":"0.72"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"1.0 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.55","upperLimit":"0.77","value":"0.67"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"1.5 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.50","upperLimit":"0.73","value":"0.63"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"2.0 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.41","upperLimit":"0.65","value":"0.54"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"2.5 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.38","upperLimit":"0.62","value":"0.51"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"3.0 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.35","upperLimit":"0.60","value":"0.48"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"3.5 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.35","upperLimit":"0.60","value":"0.48"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"4.0 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.35","upperLimit":"0.60","value":"0.48"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"4.5 years"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.35","upperLimit":"0.60","value":"0.48"},{"comment":"There was only one BAT patient responder (≥ 35% reduction in spleen volume) but no consecutive readings to determine any value for duration of response - no Median or CI possible to calculate","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"5.0 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"This is defined as the interval between randomization and date of the first MRI showing a 35% reduction from baseline in spleen volume. The analysis was performed for participants who achieved a 35% reduction in spleen volume.","dispersionType":"95% Confidence Interval","groups":[{"description":"5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule","id":"OG000","title":"Ruxolitinib"},{"description":"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria. Treatment groups were defined according to the treatment assignment at the time of randomization.","reportingStatus":"POSTED","timeFrame":"Baseline, up to Year 5","title":"Duration of Maintenance of Spleen Volume Reduction (Kaplan-Meier Estimates)","type":"SECONDARY","unitOfMeasure":"probability of response"}